Is it time to convert the frequency of radiotherapy in small-cell lung cancer?

Affiliations

¹ Oregon Health and Science University, Portland, OR 97239, USA. Electronic address: mitin@ohsu.edu.
² Oregon Health and Science University, Portland, OR 97239, USA.

Comment

Timur Mitin et al. Lancet Oncol. 2017 Oct.

. 2017 Oct;18(10):e554.

doi: 10.1016/S1470-2045(17)30581-8.

¹ Oregon Health and Science University, Portland, OR 97239, USA. Electronic address: mitin@ohsu.edu.
² Oregon Health and Science University, Portland, OR 97239, USA.

No abstract available

Comment in

Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.
Faivre-Finn C, Ryder WD, Blackhall F. Faivre-Finn C, et al. Lancet Oncol. 2017 Oct;18(10):e556. doi: 10.1016/S1470-2045(17)30611-3. Lancet Oncol. 2017. PMID: 28971815 No abstract available.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Faivre-Finn C, et al. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28642008 Free PMC article. Clinical Trial.